The increasing prevalence of multidrug-resistant Gramnegative bacteria worldwide has led to a re-evaluation of the previously discarded antibiotic, colistin. Despite its important role as salvage therapy for otherwise untreatable infections, dosage guidelines for the prodrug colistin methanesulfonate (CMS) are not scientifically based and have led to treatment failure and increased colistin resistance. In this review we summarise the recent progress made in the understanding of the pharmacokinetics of CMS and formed colistin with an emphasis on critically ill patients. The pharmacodynamics of colistin is also reviewed, with special attention given to the relationship between pharmacokinetics and pharmacodynamics and how the emerging data can be used to inform design of optimal dosage regimens. Recent data suggest the current dosage regimens of CMS are suboptimal in many critically ill patients.
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Introduction
Several highly resistant Gram-negative bacteria -namely Acinetobacter species, Pseudomonas aeruginosa and carbapenem-resistant Klebsiella species -are emerging as significant pathogens worldwide [1] . Therapeutic options for these pathogens are extremely limited, a situation made worse by the drying up of the pharmaceutical development pipeline for anti-infective agents [2] . This has forced clinicians to return to using older, previously discarded drugs, such as the polymyxins [1, 3, 4 ]. Of the two polymyxins used clinically (polymyxin B and E), the latter also known as colistin is used most widely and is the subject of this review. Having entered clinical use in 1959, colistin was never subjected to the battery of drug development procedures now mandated by international drug regulatory authorities. The result was a dearth of pharmacological information to inform rational use in order to maximize antibacterial activity and minimize toxicity and development of resistance [5] . Although colistin currently retains significant in vitro activity against many isolates of the above-mentioned Gramnegative pathogens, resistance to this crucial last-line therapy is emerging [6] [7] [8] .
Colistin is a cationic antimicrobial peptide. As a detailed review of the chemistry of colistin is beyond the scope of this article, we refer interested readers elsewhere [5, 9] . Given the relatively high level of toxicity associated with parenteral administration of colistin (sulfate) in early studies, a less toxic sulfomethyl derivative, colistin methanesulfonate (CMS), was developed [10] . Although CMS is the form administered parenterally, CMS undergoes conversion in vivo to colistin as discussed below. Importantly, it is this formed colistin that is responsible for antibacterial activity, not CMS, and thus CMS should be considered an inactive prodrug [11 ] . The active species, colistin, has a narrow antibacterial spectrum mainly against common Gram-negative bacteria including P. aeruginosa, Acinetobacter spp. and Klebsiella spp. [12] . It is against these organisms that colistin is most commonly used clinically, particularly in critically ill patients [1, 5] .
Recent investigations have unraveled key aspects of the pharmacokinetics (PK) and pharmacodynamics (PD) of colistin, and these aspects are the focus of this brief review.
Pharmacokinetics of CMS and formed colistin
Despite its availability for over 50 years, it is only with the development of HPLC and LC/MS/MS analytical methods in the past 5-10 years that an accurate picture of the PK of CMS and formed colistin has emerged. The demonstration that antimicrobial activity results from colistin, formed in vivo following administration of CMS, made the separate quantification of the inactive prodrug (CMS) and active entity (colistin) a prerequisite for accurate PK information. Before the development of these techniques, microbiological assays incapable of separately quantifying CMS and colistin were employed for measurement of 'colistin' concentrations. Importantly, the PK and prescribing information supplied with currently available parenteral products was obtained using microbiological assays.
All CMS/colistin PK data discussed below were obtained using HPLC or LC/MS/MS analytical methods. This section will focus mainly on preclinical PK studies that have involved separate administration of CMS and colistin and that have revealed key aspects of the disposition of not only the prodrug but also the active entity (colistin) formed from it in vivo. Clinical PK will be reviewed in a later section.
Following parenteral administration of CMS, the overall disposition of formed colistin is rate limited by its elimination rather than its formation as indicated by the substantially longer terminal half-life of formed colistin compared with that of the administered CMS, a finding common to both preclinical [13, 14 ] and clinical [15, 16, 17 ] studies. CMS appears to be a relatively inefficient prodrug; in rats, only a very small proportion ($7-16%) of the administered dose of CMS appears to be converted systemically to colistin [13, 14 ] . The PK of CMS and formed colistin appear linear following IV administration of CMS to rats over a range of doses generating clinically relevant plasma concentrations [14 ] . In pivotal studies conducted in rats, Li et al. demonstrated that CMS is predominantly renally cleared ($60% of the dose) with a component of tubular secretion [13] , whereas colistin is almost exclusively non-renally cleared (<1% of the dose excreted in urine) and the very low renal clearance involves very extensive renal tubular reabsorption that appears to be carrier mediated [18] . The low in vivo conversion of CMS to colistin occurs because the formation clearance of colistin is substantially less than the renal clearance of CMS [13] . Thus, the overall disposition of CMS and formed colistin is very complex. It seems very likely that the renal handling of CMS (net secretion, with the possibility of conversion of CMS to colistin within tubular cells [13] ) and formed colistin (avid tubular reabsorption [18, 19] ), processes that serve to traffic CMS/colistin through tubular cells, may be related to the propensity for CMS therapy to cause nephrotoxicity.
Pharmacodynamics of colistin
While many early reports on antibacterial activity examined both colistin and its parenteral form, CMS, it is important to note that CMS is an inactive prodrug of colistin [11 ] . Thus, activity reported with the use of CMS, whether from studies conducted in vitro or in vivo, derives from the formation of the active species, colistin. Polymyxins show excellent in vitro activity against $97% of isolates of P. aeruginosa and Acinetobacter spp. (MIC 50 , 1 mg/L and MIC 90 , 2 mg/L for both pathogens) [20] . The majority of PD data on colistin has been generated using static time-kill studies and in vitro models. Colistin displays concentration-dependent killing against susceptible strains of P. aeruginosa, A. baumannii and K. pneumoniae, including MDR strains [21] [22] [23] [24] . Colistin concentrations in the vicinity of MICs or above result in extremely rapid initial killing, with large decreases in colony forming units per mL (cfu/mL) occurring as early as 5 min following exposure. A very modest post-antibiotic effect is seen only at high concentrations against P. aeruginosa [25] . Recently, Bulitta et al. demonstrated both the rate and extent of killing by colistin are decreased at high compared to low inocula [21] . Using a genetically characterized isolate of P. aeruginosa (PAO1), killing of the susceptible population at an inoculum of 10 9 or 10 8 cfu/mL was 23-fold and 6-fold slower, respectively, compared with an inoculum of 10 6 cfu/mL. At the 10 9 inoculum, up to 32-fold higher concentrations were required to achieve bactericidal activity (!3-log 10 cfu/mL decrease) compared with the 10 6 inoculum.
Despite the often extensive initial killing observed against colistin-susceptible strains with exposure to colistin alone, regrowth is a common feature both in vitro [22, 24, 26, 27] and in vivo [28] . Regrowth of A. baumannii [23] and K. pneumoniae [24] has been reported in static time-kill studies utilizing colistin concentrations up to 64Â MIC, while Gunderson et al. [22] reported regrowth of two MDR but colistin-susceptible clinical isolates of P. aeruginosa with colistin concentrations up to 200 mg/L. Such concentrations are well in excess of those that can be safely achieved clinically (discussed subsequently). Colistin heteroresistance, the phenomenon whereby a strain deemed susceptible based upon standard MIC measurements (e.g. MIC 2 mg/L) harbors a subpopulation of colistin-resistant cells (e.g. MIC !4 mg/L), has been observed in A. baumannii [29] , K. pneumoniae [24] , and P. aeruginosa (authors unpublished data), and is probably an important contributor to regrowth and the emergence of colistin resistance. In an important study, Li et al. [30] demonstrated that colistin-resistant subpopulations in colistin-heteroresistant strains of A. baumannii had remarkably greater susceptibility, compared to their parent strains, to other antibiotics including those that normally are not active against Gram-negative bacteria.
The potential presence of colistin-resistant subpopulations before therapy, and the observation of rapid amplification of colistin-resistant subpopulations with colistin monotherapy, suggest caution with the use of colistin monotherapy and highlight the importance of investigating rational colistin combinations [4 ,30] .
Integrated pharmacokinetics/ pharmacodynamics
Recent studies investigating the relationship between the PK and PD of colistin have employed dose fractionation to determine which PK/PD index best correlates with antibacterial activity of colistin [28,31 ,32 ,33 ] . Bergen et al. [31 ] performed an extensive investigation in an in vitro PK/PD model against three strains of P. aeruginosa (including a colistin-susceptible but MDR strain) with analysis based upon unbound ( f) indices (i.e. fC max /MIC, fAUC/MIC, and fT >MIC ). Overall killing was best correlated with fAUC/MIC. In a study utilizing a neutropenic mouse thigh infection model, Ketthireddy et al. [28] reported once-daily dosing of colistin was most effective against P. aeruginosa suggesting that C max /MIC may be the PK/PD index most predictive of activity; however that conclusion could not be confirmed since PK data were not available. Dudhani et al. [32 ,33 ] employed neutropenic mouse thigh and lung infection models and determined the time course of total (i.e. protein-bound plus unbound) and unbound plasma colistin concentrations. This allowed the PK/PD analysis to be based upon unbound indices. Against three strains of each of P. aeruginosa and A. baumannii (including MDR but colistinsusceptible and, for A. baumannii, colistin-heteroresistant strains), fAUC/MIC was the index most predictive of the antibacterial effect in both thigh and lung infection models (Figure 1 ), in agreement with in vitro data [31 ] . Thus it appears that time-averaged exposure to colistin is important for its antibacterial activity. It is of note that the fAUC/MIC values associated with a given magnitude of effect (e.g. 2-log 10 reduction in viable bacteria) were generally similar across the in vitro and in vivo models, the various strains of the two bacterial species and the infection sites [31 ,32 ,33 ] . For example, the colistin fAUC/MIC values required to achieve 2-log 10 kill against 3 strains of P. aeruginosa in both thigh and lung infection models ranged from only 27.6 to 45.9 [32 ] . The identification that fAUC/MIC is the predictive index and the values of this index for different magnitudes of effect will be key to designing optimal dosage regimens for patients as more information arises on population PK in humans.
Are current dosage regimens optimal?
The simple answer to the abovementioned question is 'no' and much confusion has surrounded the 'optimal' dosing of colistin [4 ,5] . With its role as a 'salvage' therapy for otherwise untreatable infections, and with resistance to colistin beginning to emerge, it is crucial that CMS is administered in regimens that maximize antibacterial activity and minimize resistance development, while also minimizing the potential for adverse effects (e.g. nephrotoxicity). Fortunately, progress has been made recently in understanding of the PK of CMS and formed colistin in various categories of patients.
It is now evident that the currently used dosage regimens of CMS are likely to generate suboptimal exposure to colistin in many patients across various patient groups. Li et al. [15] reported that cystic fibrosis patients administered intravenous CMS had a range of peak plasma concentrations (C max ) of formed colistin of 1.2-3.1 mg/ L at steady-state. Importantly, even before consideration of protein binding plasma colistin concentrations in many cases failed to reach the CLSI breakpoint of 2 mg/L [34] defining susceptibility to colistin for P. aeruginosa and A. baumannii. Dosage regimens of CMS are also suboptimal in many critically ill patients. Markou et al. [35] and Imberti et al. [36] reported plasma colistin C max at steady-state of 1.15-5.14 mg/L and 0.68-4.65 mg/L, Relationships for P. aeruginosa ATCC 27853 between the log 10 cfu per thigh at 24 h and the PK/PD indices (a) fAUC/MIC, (b) fC max /MIC and (c) fT >MIC . Each symbol represents the mean datum per mouse from two thighs. Rrespectively, in critically ill patients with moderate to good renal function. In 18 renally competent (creatinine clearance >41 mL/min) critically ill patients, Plachouras et al. [17 ] reported a significant delay in attainment of steady-state plasma concentrations of formed colistin when CMS therapy commenced with maintenance dosing, without administration of a loading dose ( Figure 2) ; plasma colistin concentrations were well below the MIC breakpoints for the first several doses after commencing the maintenance dosage regimen with CMS. Even at steady-state, the typical plasma colistin C max was estimated to be only 2.3 mg/L, with many patients considerably below this concentration. The substantial delay between initiation of CMS therapy and attainment of steady-state observed in that study is significant not only because delayed initiation of appropriate antimicrobial therapy is associated with increased mortality in critically ill patients [37, 38] , but also because low colistin concentrations have been associated with the amplification of colistin-resistant subpopulations [24,32 ,39] . To remedy this situation, the administration of a loading dose of CMS at the commencement of therapy has been suggested [17 ,40] . In support of this, mathematical modeling by Bulitta et al. [21] predicted colistin regimens with a large colistin exposure during the first $12 h may be beneficial, providing enough net killing such that the immune system may be able to eradicate any remaining colistin-resistant cells.
In the largest population PK study to date, Garonzik et al. [41 ,42] have revealed the impact of renal function in 105 critically ill patients on the disposition of CMS and formed colistin. In that study, 89 critically ill patients with very diverse renal function not receiving renal support had average steady-state plasma colistin concentrations of 0.48-10.0 mg/L when receiving CMS daily doses selected by the treating physician (all but three patients received CMS daily doses within the currently recommended range). This study is the first to reveal that creatinine clearance is an important covariate for both the clearance of CMS and the apparent clearance of colistin. As renal function declined in these patients so too did the renal clearance of CMS, resulting in a greater fraction of the administered dose of CMS converted to colistin (hence the apparent clearance of formed colistin was lower in patients with poor renal function). Importantly, administration of CMS at the upper limit of the current product-recommended dose range to patients with moderate to good renal function resulted in low and potentially suboptimal plasma colistin concentrations. This is particularly so if the MIC of the infecting organism is in the upper range (i.e. 2 mg/L), or the infection is associated with high bacterial numbers. As suboptimal colistin concentrations may result in amplification of colistin-resistant subpopulations, the most appropriate approach is likely to be therapy with a rationally selected colistin combination regimen [4 ,30,41 ] . In 16 additional patients receiving intermittent hemodialysis (12 patients) and continuous renal replacement therapy (4 patients), both CMS and colistin underwent relatively efficient extracorporeal clearance [41 ] , which is in agreement with previous case reports [16, 43] . A very important practical outcome of this population PK study has been the generation of suggested CMS maintenance doses for various categories of critically ill patients [41 ] .
Conclusion
As more data accumulate from clinical studies, the integration of PD (clinical cure, bacteriological eradication, development of resistance) and toxicodynamic (e.g. nephrotoxicity) endpoints, together with refinements in population PK models, will help to optimize the administration of this last-line antibiotic in the various categories of patients who require it.
